175 related articles for article (PubMed ID: 32196719)
1. Aleukemia cutis: Clinicopathological and molecular investigation of two cases.
Azari-Yaam A; Safavi M; Ghanadan A
J Cutan Pathol; 2020 Aug; 47(8):747-754. PubMed ID: 32196719
[TBL] [Abstract][Full Text] [Related]
2. Myeloid sarcoma in a newborn: A rare manifestation of congenital acute myeloid leukemia.
Mullen B; Sabet K; Jacobs S; Calleroz AT; Habeshian KA; Cheng J
Pediatr Dermatol; 2023; 40(4):751-752. PubMed ID: 37029447
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M; Bacher U; Ayuk F; Lebeau A
J Clin Pathol; 2010 Jun; 63(6):558-61. PubMed ID: 20360144
[TBL] [Abstract][Full Text] [Related]
4. Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with NPM1 and FLT3 mutations.
Han S; Patel T; Garcia ML; Tirado M
J Cutan Pathol; 2024 Feb; 51(2):130-134. PubMed ID: 37866827
[TBL] [Abstract][Full Text] [Related]
5. Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review.
Elkeeb D; Hopkins Z; Miles RR; Halwani A; Wada D
Eur J Dermatol; 2018 Dec; 28(6):809-817. PubMed ID: 30698150
[TBL] [Abstract][Full Text] [Related]
6. How I treat extramedullary acute myeloid leukemia.
Bakst RL; Tallman MS; Douer D; Yahalom J
Blood; 2011 Oct; 118(14):3785-93. PubMed ID: 21795742
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous myeloid sarcoma: natural history and biology of an uncommon manifestation of acute myeloid leukemia.
Hurley MY; Ghahramani GK; Frisch S; Armbrecht ES; Lind AC; Nguyen TT; Hassan A; Kreisel FH; Frater JL
Acta Derm Venereol; 2013 May; 93(3):319-24. PubMed ID: 23165700
[TBL] [Abstract][Full Text] [Related]
8. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Cutaneous Langerhans Cell Hystiocytosis and Leukemia Cutis.
Pina-Oviedo S; Torres-Cabala CA; Miranda RN; Tetzlaff MT; Singh S; Rapini RP; Prieto VG; Aung PP
Am J Dermatopathol; 2017 May; 39(5):388-392. PubMed ID: 27759701
[TBL] [Abstract][Full Text] [Related]
11. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience.
Peker D; Parekh V; Paluri R; Deal T; Borate U; Di Stasi A; Harada S; Arroyo EA; Reddy V
Int J Hematol; 2014 Nov; 100(5):457-63. PubMed ID: 25209604
[TBL] [Abstract][Full Text] [Related]
14. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
15. Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia.
Sarvis JA; Auge BK
Urology; 2009 May; 73(5):1163.e1-3. PubMed ID: 18602141
[TBL] [Abstract][Full Text] [Related]
16. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
[TBL] [Abstract][Full Text] [Related]
17. NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis.
Karagounis TK; Rotemberg V; Geskin LJ; Jurcic JG; MDAuthors GN
Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898396
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
19. Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations.
von Keudell G; Larson RA
J Clin Oncol; 2016 May; 34(13):e123-5. PubMed ID: 24733791
[No Abstract] [Full Text] [Related]
20. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
